Abridge
-59%
est. 2Y upside i
AI & ML
Rank
#1254
Sector
Clinical AI Documentation
Est. Liquidity
~3Y
Data Quality
Data: MediumAbridge: Strong Upside with 75% expected upside.
Last updated: March 22, 2026
Bull (25%)+188%
Strong execution.
Base (50%)+75%
Steady growth.
Bear (25%)-40%
Competitive pressure.
Est. time to liquidity~3.0 years
Preference Stack Risk
moderateBuilder — 29 roles
- Clinician Scientist · San Francisco-Onsite
- Data Engineer · SF Office
- Director, Product Design - Core Product · SF Office
- +26 more →
Operations — 12 roles
- Assistant General Counsel- Privacy · United States - Remote
- Corporate Counsel - Commercial · United States - Remote
- Director, Federal Government Affairs (Washington, DC.) · United States - Remote
- +9 more →
Commercial — 10 roles
- Clinical Success Director · CHI Office
- Clinical Success Director · SF Office
- Clinical Success Director · PGH Office
- +7 more →
Last updated: February 22, 2026
Community
Valuation Sentiment
Our model estimates -59% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.